IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Burns Matteson Capital Management LLC

Burns Matteson Capital Management LLC cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,689 shares of the medical research company’s stock after selling 197 shares during the period. Burns Matteson Capital Management LLC’s holdings in IQVIA were worth $725,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of IQV. Smith Group Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $1,616,000. Simplify Asset Management Inc. boosted its position in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares during the period. Nordea Investment Management AB grew its stake in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. Fifth Third Bancorp increased its position in IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after buying an additional 1,521 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the period. Institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Truist Financial dropped their price objective on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Redburn Atlantic assumed coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. JPMorgan Chase & Co. decreased their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft reduced their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Morgan Stanley lowered their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $252.39.

IQVIA Stock Down 0.9 %

Shares of IQVIA stock opened at $208.13 on Monday. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a market capitalization of $37.78 billion, a PE ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The stock’s fifty day moving average is $200.67 and its 200-day moving average is $219.40.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.